Vivek Garipalli - 07 Aug 2025 Form 4 Insider Report for CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Role
Director, 10%+ Owner
Signature
/s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli
Issuer symbol
CLOV
Transactions as of
07 Aug 2025
Transactions value $
$998,997
Form type
4
Filing time
08 Aug 2025, 16:07:07 UTC
Previous filing
10 Jan 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garipalli Vivek Director, 10%+ Owner C/O CLOVER HEALTH INVESTMENTS, CORP., NOT APPLICABLE, WILMINGTON /s/Peter J. Rivas as attorney-in-fact for Vivek Garipalli 08 Aug 2025 0001839260

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLOV Class A Common Stock Purchase $930K +415K +29.45% $2.24 1.82M 07 Aug 2025 Direct F1
transaction CLOV Class A Common Stock Purchase $69.4K +32K +1.75% $2.17 1.86M 08 Aug 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CLOV Class B Common Stock 6.9M 07 Aug 2025 Class A Common Stock 6.9M Direct F3
holding CLOV Class B Common Stock 11.5M 07 Aug 2025 Class A Common Stock 11.5M Held by Ceasar Clover, LLC F3, F4
holding CLOV Class B Common Stock 72.1M 07 Aug 2025 Class A Common Stock 72.1M Held by NJ Healthcare Investments, LLC F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.16 to $2.32, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 1 to this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.15 to $2.21, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 2 to this Form 4.
F3 The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
F4 The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC.